{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Severe+Pneumonia",
    "query": {
      "condition": "COVID-19 Severe Pneumonia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 267,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Severe+Pneumonia&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T14:58:59.645Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04480333",
      "title": "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome (SARS) Pneumonia",
        "Severe Acute Respiratory Syndrome of Upper Respiratory Tract",
        "Neurodegeneration",
        "Neuroinflammatory Response"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831 - 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: NA-831 - 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.10 mg + 1.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.20 mg + 2.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-15",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 1,
      "location_summary": "Sunnyvale, California",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480333"
    },
    {
      "nct_id": "NCT04409262",
      "title": "A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 649,
      "start_date": "2020-06-16",
      "completion_date": "2021-03-08",
      "has_results": true,
      "last_update_posted_date": "2022-02-14",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409262"
    },
    {
      "nct_id": "NCT04482686",
      "title": "Trial of Combination Therapy to Treat COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID",
        "Covid-19",
        "Corona Virus Infection",
        "Coronavirus Infection",
        "Coronavirus-19",
        "SARS-CoV2",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "Doxycycline Hcl",
          "type": "DRUG"
        },
        {
          "name": "Zinc",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin D3",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin C",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-12-09",
      "completion_date": "2022-07-15",
      "has_results": false,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482686"
    },
    {
      "nct_id": "NCT04374461",
      "title": "A Study of N-acetylcysteine in Patients With COVID-19 Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid-19"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-05-01",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04374461"
    },
    {
      "nct_id": "NCT04425629",
      "title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "casirivimab+imdevimab combination therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10078,
      "start_date": "2020-06-16",
      "completion_date": "2022-06-09",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 102,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04425629"
    },
    {
      "nct_id": "NCT04344977",
      "title": "Collection of Anti-SARS-CoV-2 Immune Plasma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 151,
      "start_date": "2020-06-01",
      "completion_date": "2021-03-03",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 3,
      "location_summary": "Torrance, California • Miami, Florida • Seattle, Washington",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04344977"
    },
    {
      "nct_id": "NCT04492891",
      "title": "Cyclosporine For The Treatment Of COVID-19(+)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS (Disease)"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bryan Burt, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 47,
      "start_date": "2020-11-23",
      "completion_date": "2021-12-10",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492891"
    },
    {
      "nct_id": "NCT04519437",
      "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Chronic Stable Illness"
      ],
      "interventions": [
        {
          "name": "REGN10933+REGN10987",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 974,
      "start_date": "2020-07-26",
      "completion_date": "2021-11-22",
      "has_results": false,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 7,
      "location_summary": "Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04519437"
    },
    {
      "nct_id": "NCT04766931",
      "title": "The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "FB2001",
          "type": "DRUG"
        },
        {
          "name": "FB2001 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Frontier Biotechnologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 88,
      "start_date": "2021-03-17",
      "completion_date": "2022-08-12",
      "has_results": false,
      "last_update_posted_date": "2022-11-28",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04766931"
    },
    {
      "nct_id": "NCT05254990",
      "title": "Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infectious Pneumonia",
        "Severe COVID-19"
      ],
      "interventions": [
        {
          "name": "Reparixin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 414,
      "start_date": "2022-04-27",
      "completion_date": "2024-09-27",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-06-10T14:58:59.645Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • Orange, California • Denver, Colorado + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05254990"
    }
  ]
}